Journal of Drugs in Dermatology最新文献

Background: Hidradenitis suppurativa (HS) is a multifactorial disease that presents with chronic cycles of inflammation, healing, and scarring and that elicits a profoundly negative impact on patient quality of life regarding self-image, fear of stigmatization, and social isolation. Patients commonly develop painful, odorous abscesses that evolve into draining sinus tracts and disfiguring scarring.

Objective: While systemic medications and surgical therapies are often effective in reducing active lesion activity and inflammation, these therapies sometimes only provide modest success in the prevention of future recurrences and disease progression, warranting adjunctive therapies such as laser and light-based therapies.1 Herein, this systematic review has been conducted to assess the current level of evidence supporting intense pulsed light (IPL) and laser treatment for HS, with a focus on a decrease in the number of lesions with associated HS flares.

Methods: GRADE assessments were performed using PubMed and Scopus. Of 428 studies identified, 10 studies (n= 235) evaluated IPL or laser hair removal treatment and their effectiveness in reducing HS flares.

Results: Significant reductions in the overall count of inflammatory lesions were observed in all studies, with percentages ranging from 50% to 75%, and in some cases, achieving complete resolution. However, durations of disease remission varied.

Conclusion: These results provide a moderate level of evidence supporting the effectiveness of IPL and laser hair removal as adjunctive therapy in the treatment of HS; however, further long-term studies are required to provide future guidance on the most effective treatment duration and intervals for sustaining disease clearance. J Drugs Dermatol. 2024;23(11):926-930. doi:10.36849/JDD.8627.

We evaluated real-life experiences of a topical neuro-peptide serum containing 2% acetyl hexapeptide-8, 2% dipeptide diaminobutyroyl, 5% polyhydroxy acids (PHA), 5% niacinamide, and 1% laminaria extract (topical neuro-peptide serum [TNP-serum]). The TNP-serum works synergistically by stimulating 9 key skin biomarkers to reduce wrinkles and produce a skin-brightening effect. Here, we highlight the real-life experiences of 5 dermatologists and 2 surgeons, using an integrated skincare regimen consisting of botulinum toxin type-A (BTX-A) injection in conjunction with twice daily TNP-serum. Real-world cases provide evidence for combination treatments that may be used in cosmetic dermatology to improve patient outcomes and satisfaction. TNP-serum appears to complement BTX-A injections to improve radiance, reduce fine lines, and reduce wrinkles in diverse patients. Incorporating TNP-serum into integrated skincare regimens may offer an additive effect to BTX-A injections and, ultimately, optimize patient results. J Drugs Dermatol. 2024;23:11(Suppl 2):s3-14.

Background: Effective treatment of acne remains a challenge to dermatologists.

Objective: To evaluate the efficacy and tolerability of a 650-microsecond, pulsed 1064-nm Nd:YAG laser therapy for mild to severe facial acne vulgaris.

Methods: Human subjects of Fitzpatrick skin types I to VI with mild, moderate, or severe acne enrolled in the prospective, single-center study. Subjects received 5 treatments at 2-week intervals with the 650-microsecond, 1064-nm, pulsed Nd:YAG laser. Follow-up visits were 30 days and 90 days after the final treatment. At each visit, subject global assessments, lesion counts, investigator's global assessments (IGAs), and tolerability appraisals were performed.

Results: The median percent reduction in lesion count was 48.15% after 1 treatment and 83.72% at treatment 3 and remained at 86.67% at 90 days. Sixty percent of subjects noted improvement after treatment 1, and most subjects noticed improvement on or before treatment 3. Median IGA values decreased rapidly to reach a plateau of 1.0 (almost clear) at week 6 and remained there at the 30- and 90-day follow-up. Ninety percent of subjects were slightly to highly satisfied after 3 treatments, and 90% slightly to strongly agreed that their acne treatments improved their self-esteem after 4 treatments. Anesthesia or skin cooling were not used, and adverse events were not observed.

Conclusions: The 650-microsecond, pulsed 1064-nm Nd:YAG laser has been proven to deliver long-lasting clearance of mild to severe facial acne vulgaris with high subject satisfaction and without adverse effects on skin types I to VI. J Drugs Dermatol. 2024;23(11):957-964. doi:10.36849/JDD.8171.

Background: Androgenetic Alopecia (AGA) (male pattern hair loss) is the most common form of alopecia in men, affecting 30% of men by the age of 30 years and 50% by the age of 50 years.

Objective: To compare the efficacy of topical finasteride 0.25% with minoxidil 5% versus topical minoxidil 5% alone in the treatment of male pattern androgenic alopecia.

Methods: A total of 164 male patients aged between 30 and 60 years, presenting with androgenic alopecia of more than 2 months duration, were included in this single-blind study conducted at the Department of Dermatology, JPMC, Karachi. The patients were randomly divided into two groups: Group A (topical finasteride 0.25% with minoxidil 5%) and Group B (topical minoxidil 5% alone). Patients were followed up for 12 weeks, and hair regrowth was assessed at each visit.

Results: The mean age in Group A was 33.99±5.97 years, and in Group B, it was 33.91±5.71 years. At baseline, the mean salt score was 1.8±0.7 in both groups. The efficacy of the treatment was significantly higher in Group A (86.7%) compared to Group B (69.1%; P=0.006).

Conclusion: The combination of topical finasteride 0.25% with minoxidil 5% provides superior efficacy in the treatment of male pattern androgenic alopecia compared to topical minoxidil 5% alone. These findings support the use of this combination therapy as a potential treatment option for patients with androgenic alopecia. J Drugs Dermatol. 2024;23(11):1003-1008. doi:10.36849/JDD.7826.

We, as dermatologists, are exceedingly lucky.  We can watch our patients improve before our eyes. In clinical practice, we don't often track a quantitative metric to gauge success but rather measure the success of our treatment by the appearance of our patients' skin.

Acne vulgaris is an extremely common dermatologic condition. Individuals with acne present not only to dermatologists, but also to internists, family medicine physicians, pediatricians, estheticians, and beauty counters alike in search of a treatment. The diagnosis of acne is relatively straightforward, leading many to believe that acne is a simple condition. However, the pathophysiology of acne is anything but simple. Decades of research has ultimately revealed a complex interaction of pathogenic factors that lead to acne. This includes sebum production, C. acnes colonization, inflammation, and follicular hyperkeratinization. Understanding each of these features has been fundamental to the development of anti-acne medications. Topical agents are often used as an initial therapy given their safety and efficacy. While some topical therapies have been used for decades, new creams, gels, and lotions continue to be added to the list of approved acne treatments. Given the number of topical acne products on the market, we present an updated review of the current landscape of topical acne treatments and how each choice functions mechanistically to fight against acne. J Drugs Dermatol. 2024;23:10(Suppl 1):s4-11.

Janus kinase inhibitors (JAKis) have recently emerged in the arsenal of tools to treat dermatological conditions. However, there are some concerns regarding these treatments due to their boxed warning. Here we discuss the safe and effective use of JAKs for the treatment of a wide variety of dermatologic conditions. We will also discuss monitoring guidelines. J Drugs Dermatol. 2024;23(10):852-856. doi:10.36849/JDD.8073.